Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

Samuel FrankBoston University School of Medicine, Boston, Massachusetts, USAAbstract: Huntington disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Samuel Frank
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/21be499c52914b2eaec60e9b04de8980
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21be499c52914b2eaec60e9b04de8980
record_format	dspace
spelling	oai:doaj.org-article:21be499c52914b2eaec60e9b04de89802021-12-02T07:10:52ZTetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease1176-63281178-2021https://doaj.org/article/21be499c52914b2eaec60e9b04de89802010-09-01T00:00:00Zhttp://www.dovepress.com/tetrabenazine-the-first-approved-drug-for-the-treatment-of-chorea-in-u-a5378https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Samuel FrankBoston University School of Medicine, Boston, Massachusetts, USAAbstract: Huntington disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to those at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate mainly involving the neurotransmitters dopamine, glutamate, and &gamma;-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This review will address the epidemiology and diagnosis of HD as background for understanding potential pharmacological treatment options. Because TBZ is the only US Food and Drug Administration-approved medication in the United States for HD, the focus of this review will be on its pharmacology, efficacy, safety, and practical uses. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD.Keywords: dopamine-depleting agent, neuroleptics, tetrabenazine Samuel FrankDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 657-665 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Samuel Frank Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
description	Samuel FrankBoston University School of Medicine, Boston, Massachusetts, USAAbstract: Huntington disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to those at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate mainly involving the neurotransmitters dopamine, glutamate, and &gamma;-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This review will address the epidemiology and diagnosis of HD as background for understanding potential pharmacological treatment options. Because TBZ is the only US Food and Drug Administration-approved medication in the United States for HD, the focus of this review will be on its pharmacology, efficacy, safety, and practical uses. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD.Keywords: dopamine-depleting agent, neuroleptics, tetrabenazine
format	article
author	Samuel Frank
author_facet	Samuel Frank
author_sort	Samuel Frank
title	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
title_short	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
title_full	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
title_fullStr	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
title_full_unstemmed	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
title_sort	tetrabenazine: the first approved drug for the treatment of chorea in us patients with huntington disease
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/21be499c52914b2eaec60e9b04de8980
work_keys_str_mv	AT samuelfrank tetrabenazinethefirstapproveddrugforthetreatmentofchoreainuspatientswithhuntingtondisease
_version_	1718399559528349696

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

Ejemplares similares